Listen
SODIUM BICARBONATE 1.4% RENAUDIN (sodium bicarbonate) - metabolic acidosis
Opinions on drugs -
Posted on
Jul 29 2024
Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the correction of metabolic acidosis.
No clinical added value of the new form compared to the forms already available.
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of the proprietary medicinal product SODIUM BICARBONATE 1.4% RENAUDIN solution injectable, packaged in packs of ten 10-ml vials is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed. |
